Clinics, 2012 OBJECTIVES: The clinical significance of ischemia/reperfusion of the lower extremities demands further investigation to enable the development of more effective therapeutic alternatives.
Mariana R.G.A. Santos +5 more
doaj +1 more source
Use of Cilostazol for Secondary Stroke Prevention: An Old Dog with New Tricks? [PDF]
, 2012 OBJECTIVE: To evaluate the safety and efficacy of cilostazol for secondary prevention of non-cardioembolic ischemic stroke. DATA SOURCES: PubMed and MEDLINE searches were performed (January 1970-September 2011) using the key words cilostazol ...
Ansara, Alex J. +2 more
core +2 more sources
5. THE EFFECT OF CILOSTAZOL TO ARTERIAL STIFFNESS IN THE HYPERTENSIVE PATIENT
Artery Research, 2009 Background: Cilostazol is a potent antiplatelet agent that selectively inhibits phosphodiesterase III, and also it has beneficial effect to peripheral arterial disease, like intermittent claudication, by direct vasodilative action.
Jin Oh Na +8 more
doaj +1 more source
Rationale and design of "Can Very Low Dose Rivaroxaban (VLDR) in addition to dual antiplatelet therapy improve thrombotic status in acute coronary syndrome (VaLiDate-R)" study : A randomised trial modulating endogenous fibrinolysis in patients with acute coronary syndrome [PDF]
, 2019 © The Author(s) 2019. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the ...
Gorog, Diana A +5 more
core +2 more sources
Cilostazol protects hepatocytes against alcohol-induced apoptosis via activation of AMPK pathway.
PLoS ONE, 2019 Alcoholic liver disease (ALD) is a worldwide health problem and hepatocyte apoptosis has been associated with the development/progression of ALD. However, no definite effective pharmacotherapy for ALD is currently available.
Youn Ju Lee +6 more
doaj +1 more source
Efficacy of cilostazol on platelet reactivity and cardiovascular outcomes in patients undergoing percutaneous coronary intervention: insights from a meta-analysis of randomised trials [PDF]
, 2014 Background: Cilostazol overcomes high on-treatment platelet reactivity (HTPR) and reduces adverse cardiovascular (CV) outcomes after percutaneous coronary intervention (PCI).
Bangalore, Sripal +6 more
core +1 more source
Clinical and Pathological Improvement in Stroke-Prone Spontaneous Hypertensive Rats Related to the Pleiotropic Effect of Cilostazol [PDF]
, 2012 Background and Purpose-Cerebral infarction is a major cause of death or decreasing activities of daily living. This study aimed to investigate the efficacy of commonly used antiplatelet drugs on stroke and motor and cognitive functions in relation to ...
Abe, Koji +7 more
core +1 more source
New Therapeutic Approaches for Alzheimer’s Disease and Cerebral Amyloid Angiopathy [PDF]
, 2014 Accumulating evidence has shown a strong relationship between Alzheimer’s disease (AD), cerebral amyloid angiopathy (CAA), and cerebrovascular disease.
Masafumi Ihara, Satoshi Saito
core +2 more sources
A Paclitaxel-Eluting Stent for the Prevention of Coronary Restenosis [PDF]
, 2003 Background Intimal hyperplasia and resulting restenosis limit the efficacy of coronary stenting. We studied a coronary stent coated with the antiproliferative agent paclitaxel as a means of preventing restenosis.
Choi, D +11 more
core +1 more source
Newer agents in antiplatelet therapy: a review. [PDF]
, 2012 Antiplatelet therapy remains the mainstay in preventing aberrant platelet activation in pathophysiological conditions such as myocardial infarction, ischemia, and stroke.
Holinstat, Michael, Yeung, Jennifer
core +3 more sources